3 trials changed in the last 30 days: 0 stopped, 2 with notable changes, 1 with a minor change only.
Recruitment opened
Guangdong Provincial People's HospitalPhase 2/3 NCT07410169 Registry history of NCT07410169 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Guangdong Provincial People's HospitalPhase 2 NCT07722754 Registry history of NCT07722754 on ClinicalTrials.gov (opens the registry)
Updated
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Guangdong Provincial People's HospitalNot applicable NCT05841186 Registry history of NCT05841186 on ClinicalTrials.gov (opens the registry)
Changed
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-09-25 | NCT07842471 Local Consolidative Therapy Versus Maintenance Immunotherapy After First-Line… | Phase 2 | Not Yet Recruiting |
| Early Phase 1 | 1 | |
| Phase 1 | 2 | |
| Phase 1/2 | 2 | |
| Phase 2 | 19 | |
| Phase 2/3 | 1 | |
| Phase 3 | 5 | |
| Phase 4 | 6 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 4 | ||||
| NCT06738992 | Safety and Effectiveness of Early Aspirin Administration After Mitral Valve Repair | Mitral Valve Repair Surgery | Recruiting | 2024-12-18 |
| NCT06506838 | Anlotinib Combined With Doxorubicin and Radiotherapy as Neoadjuvant Treatment for Soft… | Soft Tissue Sarcoma | Recruiting | 2024-08-12 |
| NCT04381143 | ASPIrin in Reducing Events in Dialysis ( ASPIRED ) | CKD (Chronic Kidney Disease) Stage 5D | Active, Not Recruiting | 2026-09-14 |
| NCT07483398 | EFficacy and safEty of cRisugabalin on nocipLastic paIn in Patients With Parkinson's… | PARKINSON DISEASE (Disorder) | Active, Not Recruiting | 2026-09-14 |
| NCT06956157 | NAC for Treatment-Resistant OCD and Other Related Disorders | Obsessive Compulsive Disorder (OCD) | Active, Not Recruiting | 2025-09-03 |
| NCT06498050 | Brolucizumab Efficacy and Safety Single-Arm Descriptive Trial in Patients With Persistent… | Diabetic Macular Edema | Active, Not Recruiting | 2025-06-04 |
| Phase 3 | ||||
| NCT07016126 | D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or… | NSCLC (Non-small Cell Lung Cancer) | Recruiting | 2025-06-11 |
| NCT06533384 | PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC | Triple-negative Breast Cancer | Recruiting | 2024-11-04 |
| NCT07748260 | De-escalation Neoadjuvant Therapy for Intermediate Risk HER2-positive Early Breast | HER2-positive Breast Cancer | Not Yet Recruiting | 2026-08-05 |
| NCT07686796 | Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With… | Local Advanced Rectal Cancer | Not Yet Recruiting | 2026-07-07 |
| NCT04946734 | Effectivity and Safety of PFO Closure vs Medicine in Alleviating Migraine | PFO - Patent Foramen Ovale | Active, Not Recruiting | 2025-03-12 |
| Phase 2/3 | ||||
| NCT07410169 | Efficacy and Safety of Hyperbaric Oxygen Therapy in Improving Nab-paclitaxel-Induced… | Breast Cancer | Recruiting | 2026-09-30 |
| Phase 2 | ||||
| NCT07722754 | Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic… | Colorectal Neoplasms Malignant | Recruiting | 2026-09-24 |
| NCT06451861 | Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or… | Acute Myeloid Leukemia | Recruiting | 2025-11-17 |
| NCT05272696 | Pembrolizumab and Induction Chemotherapy in Locally Advanced HNSCC | Head and Neck Squamous Cell Carcinoma | Recruiting | 2025-07-01 |
| NCT06911606 | Study of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small… | SCLC, Limited Stage | Recruiting | 2025-04-04 |
| NCT06734182 | Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant… | Non-small Cell Lung Cancer | Recruiting | 2024-12-16 |
| NCT06102824 | Organoid-based Functional Precision Therapy for Advanced Breast Cancer | HER2-negative Breast Cancer | Recruiting | 2024-11-25 |
| NCT05954897 | Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular… | Hepatocellular Carcinoma | Recruiting | 2023-07-20 |
| NCT05800340 | Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC | Non-Small Cell Lung Cancer | Recruiting | 2023-04-05 |
| NCT07842471 | Local Consolidative Therapy Versus Maintenance Immunotherapy After First-Line… | NSCLC (Non-small Cell Lung Carcinoma) | Not Yet Recruiting | 2026-09-25 |
| NCT07738328 | Terbinafine for CSA-AKI Prevention | Acute Kidney Injury | Not Yet Recruiting | 2026-07-31 |
| NCT06933251 | PCSK9 Inhibitor and PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy for… | Locally Advanced Rectal Cancer (LARC) | Active, Not Recruiting | 2026-07-08 |
| NCT06300424 | Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC | Non Small Cell Lung Cancer | Active, Not Recruiting | 2026-04-29 |
| NCT07521605 | Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced… | Rectal Cancer Patients | Not Yet Recruiting | 2026-04-13 |
Lung Cancer (19) · Breast Cancer (12) · Heart Disease (12) · Non-Small Cell Lung Cancer (NSCLC) (12) · Chronic Kidney Disease (5) · Colorectal Cancer (5) · Hypertension (4) · Anxiety (3) · Heart Failure (3) · Leukemia (3)